Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

News SummaryMost relevantAll newsSector newsTweets 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
03/05/2013 | 10:15am CEST

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at [email protected]/ +91-40-66834297
Saunak Savla at [email protected]/ +91-40-49002135
Milan Kalawadia (USA) at [email protected]/ +1 908-203-4931

S Rajan at [email protected]/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
06/21 DR REDDY LABORATORIES : May file 2 new drugs with fda by 2019
06/21 DR REDDY LABORATORIES : New drug application
06/15 India stocks higher at close of trade; Nifty 50 up 0.12%
06/15 DR REDDY LABORATORIES : USFDA gives EIR to Dr Reddys Laboratories API plant in T..
06/15 DR REDDY LABORATORIES : Usfda gives eir to drl's api plant in telangana
06/14 DR REDDY LABORATORIES : . Reddy's gets EIR from USFDA for Miryalaguda plant
06/07 DR REDDY LABORATORIES : Launches bivalirudin
06/06 DR REDDY LABORATORIES : Announces the Launch of Bivalirudin for Injection in the..
06/06 DR REDDY LABORATORIES : announces the launch of Bivalirudin for Injection in the..
06/05 DR REDDY LABORATORIES : to Present at the Jefferies 2017 Global Healthcare Confe..
More news
Sector news : Pharmaceuticals - NEC
06/27DJMERCK AND : Says Its Network Was Hit by Global Hack
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/27 Aralez Pharma prevails in Vimovo patent challenge
06/21 FDA aims at removing barriers to generic drug competition
06/07 Dr. Reddy's Laboratories Limited (RDY) Presents At Jefferies 2017 Global Heal..
06/06 Dr. Reddy's launches generic Angiomax in U.S.
06/05 Mallinckrodt down 7% on new Citron report
Financials ( INR)
Sales 2018 156 493 M
EBIT 2018 23 542 M
Net income 2018 18 628 M
Debt 2018 5 689 M
Yield 2018 0,78%
P/E ratio 2018 23,75
P/E ratio 2019 17,80
EV / Sales 2018 2,84x
EV / Sales 2019 2,39x
Capitalization 438 331 M
More Financials
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Full-screen chart
Technical analysis trends DR.REDDY'S LABORA...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 41
Average target price 2 812  INR
Spread / Average Target 6,4%
Consensus details
EPS Revisions
More Estimates Revisions
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER4.80%203 487
MERCK AND COMPANY11.98%180 958
More Results